

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/728,323
		Filing Date	December 4, 2003
		First Named Inventor	Michael J. Caplan
		Art Unit	1644
		Examiner Name	P. N. Huynh
		Attorney Docket Number	2006517-0010
Sheet	1	of	3

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1*	US-20020187158	12-12-2002	Mahler et al.	
	A2*	US-20030082190	05-01-2003	Saxon et al.	
	A3*	US-3,097,141	07-09-1963	Kidwell	
	A4*	US-5,389,368	02-14-1995	Curtiss, III	
	A5*	US-5,547,669	08-20-1996	Rogers et al.	
	A6*	US-5,811,128	09-22-1998	Tice et al.	
	A7*	US-5,830,463	11-03-1998	Duke et al.	
	A8*	US-5,834,246	11-10-1998	Holmgren et al.	
	A9*	US-5,888,799	03-30-1999	Curtiss, III	
	A10*	US-6,004,815	12-21-1999	Portnoy et al.	
	A11*	US-6,025,162	02-15-2000	Rogers et al.	
	A12*	US-6,086,898	07-11-2000	DeKruyff et al.	
	A13*	US-6,187,311	02-13-2001	Nishiyama et al.	
	A14*	US-6,221,648	04-24-2001	Le Page et al.	
	A15*	US-6,239,116	05-29-2001	Krieg et al.	
	A16*	US-6,270,723	08-07-2001	Laugham, Jr. et al.	
	A17*	US-6,486,311	11-26-2002	Burks, Jr. et al.	
	A18*	US-6,506,388	01-14-2003	Shionoya et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	
		Country Code ² -Number ³ -Kind Code ⁴ (if known)				
	B1**	EP-0080806-A1	06-08-1983	Research Corp		
	B2**	WO-198809669	12-15-1988	Molecular Engineering		
	B3**	WO-199214487	09-03-1992	Holmgren et al		
	B4**	WO-199614876	05-23-1996	The Regents of the University of Colorado		
	B5**	WO-199724139	03-03-1994	Dana Farber Cancer Institute		
	B6**	WO-199823763	06-04-1998	The General Hospital Corporation		
	B7**	WO-199844096	10-08-1998	Cyto-Clonal Pharmaceuticals Inc.		
	B8**	WO-199925387	05-27-1999	Washington University		
	B9**	WO-199938978	08-05-1999	University of Arkansas et al		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with a single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. ** CITE NO.: Those document(s) which are marked with a double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
4723707v1	

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/728,323
		Filing Date	December 4, 2003
		First Named Inventor	Michael J. Caplan
		Art Unit	1644
		Examiner Name	P. N. Huynh
Sheet	2	of	3
		Attorney Docket Number	2006517-0010

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1**	Aalberse et al, 2000, J Allerg Clin Immunol, 106:228-38	
	C2**	Andrews et al, 1996, Gene, 182:101-9	
	C3**	Blumental et al, 2004, Allergens and Allergen Immunotherapy, 3rd Ed, 37-50	
	C4**	Burks et al, 1995, J. Clin. Invest., 96:1715-21	
	C5**	Burks et al, 1997, Eur J Biochem, 245:334-39	
	C6**	Burks et al, 1999, Int Arch Allerg Immunol, 118:313-14	
	C7**	Chatel et al, 2003, Allergy, 58:641-47	
	C8**	Chong et al, 1997, Transgenic Res, 289-296	
	C9**	Colman et al, 1994, Res Immunol, 145:33-36	
	C10**	Dizier et al, 1999, Gen Epidemiol, 16:305-15	
	C11**	Eidelman et al, 1988, Am Rev Respir Dis, 137:1033-37	
	C12**	Eko et al, 1999, Vaccine, 17:1643-49	
	C13**	Evans et al, 1998, FEMS Microbiol Immunol, 47:117-25	
	C14**	Fasler et al, 1998, J Allerg Clin Immunol, 101:521-30	
	C15**	Fenton et al, 1995, J Natl Canc Inst, 87:1853-61	
	C16**	Ferreira et al, 1996, J. Exp. Med., 183:599-609	
	C17**	Ferreira et al, 1998, FASEB J, 12:231-42	
	C18**	Gentschev et al, 1996, Gene, 179:133-40	
	C19**	Gottlieb et al, 1999, BMJ, 318:894	
	C20**	Greenspan et al, 1999, Nat Biotechnol, 17:936-37	
	C21**	Hansen et al, 2000, J. Immunol., 164:223-30	
	C22**	Harvey et al, 1990, Remington's Pharmaceutical Sciences, 18th Ed., Chapter 35, p 711	
	C23**	Hess et al, 1996, Proc Natl Acad Sci, USA, 93:1458-63	
	C24**	Higgins et al, 1999, Mol Microbiol, 31:1631-41	
	C25**	Hoffman et al, 1975, Immunochemistry, 12:535-38	
	C26**	Ingram et al, 1980, J Bact, 144:481-88	
	C27**	James et al, 1997, J Allerg Clin Immunol, 99(1):239-44 part 2	
	C28**	Kleber-Janke et al, 2000, Prot Exp Purificat, 19:419-24	
	C29**	Komanapalli et al, 1998, Appl Microbiol Biotechnol, 49:766-69	
	C30**	Kraft et al, 1999, Int Arch Allerg Immunol, 118:171-76	
	C31**	Leclerc et al, 1990, J Immunol, 144:3174-82	
	C32**	Li et al, 2003, J. Allergy Clin. Immunol., 112(1):160-167	
	C33**	Li, 1999, J. Immunol., 162:3045-52	
	C34**	Mekalanos, 1992, Gen Eng Vaccines, 327:43	
	C35**	Rabjohn et al, 1999, J Clin Invest, 103:535-42	
	C36**	Reese et al, 2005, J Immunol, 175:8354-64	
	C37**	Skolnick et al, 2000, Trend Biotech, 18:34-39	
	C38**	Stanley et al, 1997, Arch Biochem Biophys, 342:244-53	
	C39**	Till, 2004, Allergens and Allergen Immunotherapy, 3rd Ed, 85-104	
	C40**	Vrtala et al, 1995, Int Arch Allerg Immunol, 107:290-94	
	C41**	Vrtala et al, 1997, J Clin Invest, 99(7):1673-81	

Examiner Signature 4723707v1	Date Considered
--	------------------------

Substitute for form 1449PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/728,323		
		Filing Date	December 4, 2003		
		First Named Inventor	Michael J. Caplan		
		Art Unit	1644		
		Examiner Name	P. N. Huynh		
Sheet	3	of	3	Attorney Docket Number	2006517-0010

	C42**	Walker et al, 1994, Vaccine, 12:387-400	
	C43**	Yeung et al, 1998, J Immunol, 161:4146-52	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

4723707v1